Skip to content
Medical Health Aged Care

New Paediatric Palliative Care Decision-Making Tool helps health professionals ‘Know the Right Time’ for referrals

Palliative Care Australia 2 mins read
 
 

Palliative Care Australia (PCA) has launched a new Timely Referral Paediatric Palliative Care Decision-Making Guideline Tool, developed to support health professionals in identifying the right time to refer children, young people, and their families to paediatric palliative care. 

The tool was developed as part of the Shaping the Future Paediatric Palliative Care Project funded by the Australian Government and was a key action identified in the Paediatric Palliative Care National Action Plan. 

An awareness campaign – Know the Right Time – has also been launched this week to coincide with the decision-making tool’s release, to encourage clinicians to reflect on when and how to make referrals that best support families from diagnosis through to end-of-life care. 

Palliative Care Australia CEO Camilla Rowland said the new decision-making tool was developed over 18 months in close collaboration with families, paediatric palliative care specialists, and referring clinicians including neurologists, oncologists, cardiologists, and neonatologists.  

“The tool supports reflective practice, helping clinicians assess a child’s medical condition, psychosocial context, and family needs to determine when referral is appropriate,” Ms Rowland said. 

“Although ‘palliative care’ can be a confronting term, a timely referral can offer valuable additional support to children, families and their care teams.  

“Early involvement allows time to understand what matters most to a child and their family, supports informed decisions, and ensures effective symptom management. It also allows time for important conversations, sibling support, and greater choice – improving quality of life. 

“Late referrals greatly reduce the ability to provide these important care interventions, meaning families may not get the support they need when they need it most. It may also result in care teams wondering if things could have been done differently.” 

Ms Rowland said that the decision-making support tool highlights that timely referral is not simply about assessing a stage of illness, but about ensuring families have the right support at the right time. 

“Historically, slow referral to paediatric palliative care has limited the support available to children and families. The need for this tool will only grow with an estimated 41,775 children and young people aged 0 to 21 years, who might benefit from paediatric palliative care services by 2027. 

“For clinicians, families, and palliative care teams alike, the message is clear: Know the right time – because timely referral can change the course of care and support for every child and family,” Ms Rowland said. 

The Timely Referral Paediatric Palliative Care Decision-Making Guideline Tool is now available for download in both short and full versions: https://paediatricpalliativecare.org.au/resource/referral-to-paediatric-palliative-care-decision-making-guideline-tool-for-health-professionals/ 

 

Notes to Editors 

A report released by Australian Institute of Health and Welfare (AIHW) in 2024 found that one in three children who received specialist paediatric palliative care had been engaged with the service for less than one month before their death. This reflects a continuing pattern of late referral, despite long-standing recommendations for early involvement. Source: https://www.aihw.gov.au/reports/palliative-care-services/paediatric-palliative-care-for-children-who-died/summary 

 

 


About us:

Palliative Care Australia is the national peak body for palliative care.


Contact details:

For media enquiries, please contact Jillian Marsh on 0413 160 333 or email [email protected] and [email protected] 

Media

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.